Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.43 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.42 |
| ▸ | EP300 | Q09472 | 9/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.36 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.35 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.35 |
| ▸ | ALB | P02768 | 2/20 | 0.35 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.35 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23343373 | 0.85 | FGFR1 (0.44) | FGFR1SLC22A6EP300MAPTLMNA | |
| SCHEMBL24709494 | 0.85 | FGFR1 (0.44) | FGFR1SLC22A6EP300MAPTLMNA | |
| SCHEMBL6379845 | 0.83 | FGFR1 (0.43) | FGFR1SLC22A6EP300MAPTLMNA | |
| SCHEMBL5016785 | 0.81 | FGFR1 (0.43) | FGFR1SLC22A6EP300MAPTLMNA | |
| SCHEMBL3680116 | 0.81 | FGFR1 (0.52) | FGFR1SLC22A6EP300MAPTLMNA | |
| SCHEMBL22078831 | 0.81 | FGFR1 (0.43) | FGFR1SLC22A6EP300MAPTLMNA | |
| SCHEMBL2967556 | 0.81 | FGFR1 (0.43) | FGFR1SLC22A6EP300MAPT | |
| SCHEMBL3260493 | 0.81 | FGFR1 (0.43) | FGFR1SLC22A6EP300MAPTLMNA | |
| SCHEMBL30364554 | 0.81 | HTR2C (0.46) | FGFR1SLC22A6EP300MAPTCYP2D6 | |
| SCHEMBL16446911 | 0.80 | FGFR1 (0.47) | FGFR1SLC22A6EP300MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673136-B2 | Nanopore devices for sensing biomolecules | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2023-06-13 | — | — | US | disclosed |
| US-20190317040-A1 | DEVICES AND METHODS FOR TARGET MOLECULE CHARACTERIZATION | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2019-10-17 | — | — | US | disclosed |
| US-10442771-B2 | Trans-base tunnel reader for sequencing | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180280968-A1 | NANOPORE DEVICES FOR SENSING BIOMOLECULES | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2018-10-04 | — | — | US | disclosed |
| US-20170204066-A1 | NANOPORE BASED SEQUENCER | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2017-07-20 | — | — | US | disclosed |
| US-9593372-B2 | Nanopore based sequencer | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2017-03-14 | — | — | US | disclosed |
| US-9395352-B2 | Devices and methods for target molecule characterization | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150211059-A1 | TRANS-BASE TUNNEL READER FOR SEQUENCING | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2015-07-30 | — | — | US | disclosed |
| US-8968540-B2 | Trans-base tunnel reader for sequencing | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2015-03-03 | — | — | US | disclosed |
| US-8961757-B2 | Nanopore and carbon nanotube based DNA sequencer | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2015-02-24 | — | — | US | disclosed |
| US-20100084276-A1 | Devices and Methods for Target Molecule Characterization | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-08 | — | — | US | disclosed |
| WO-2009117522-A2 | NANOPORE AND CARBON NANOTUBE BASED DNA SEQUENCER AND A SERIAL RECOGNITION SEQUENCER | REINHART, KEVIN (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009117517-A2 | NANOPORE AND CARBON NANOTUBE BASED DNA SEQUENCER | ARIZONA BOARD OF REGENTS ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2008124706-A9 | DEVICES AND METHODS FOR TARGET MOLECULE CHARACTERIZATION | UNIV ARIZONA STATE (US) | 2009-05-28 | — | — | WO | disclosed |
| EP-1313751-B1 | NEW MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| US-6740642-B2 | ACTIVE AGAINST GRAM POSITIVE PATHOGENS SUCH AS STAPHYLOCOCCUS AUREUS, STREPTOCOCCUS PNEUMONIAE, GRAM NEGATIVE STRAINS SUCH AS HAEMOPHILUS INFLUENZAE; IMPROVED STABILITY | BASILEA PARMACEUTICA AG (CH) | 2004-05-25 | — | — | US | disclosed |
| US-20030199459-A1 | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG, A SWISS COMPANY (CH) | 2003-10-23 | — | — | US | disclosed |
| EP-1313751-A1 | NEW MACROLIDES WITH ANTIBACTERIAL ACTIVITY | Basilea Pharmaceutica AG (CH) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002016380-A1 | NEW MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2002-02-28 | — | — | WO | disclosed |
| WO-1999063111-A2 | METHOD OF LABELLING NUCLEIC ACID | EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204066-A1 | NANOPORE BASED SEQUENCER | DNMT3A, DNTT, TELO2 | FGFR1 3192/4885SLC22A6 1053/4885EP300 4612/4885 |
| US-10442771-B2 | Trans-base tunnel reader for sequencing | DNTT, TRDMT1, TELO2 | FGFR1 3902/4885SLC22A6 315/4885EP300 4441/4885 |
| US-20030199459-A1 | Macrolides with antibacterial activity | MRPL21, MRPS22, MRPL12 | FGFR1 1575/4885SLC22A6 521/4885EP300 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.